6,562 results match your criteria Journal of Thrombosis and Haemostasis[Journal]


Intraoperative infusion of noradrenaline improves platelet aggregation in patients undergoing coronary artery bypass grafting: a randomized controlled trial.

J Thromb Haemost 2019 Feb 14. Epub 2019 Feb 14.

Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Background: New approaches to prevent bleeding complications during cardiac surgery are needed.

Objective: To investigate if noradrenaline (NA) enhances platelet aggregation in CABG patients.

Patients/methods: Twenty-four CABG patients were included in a prospective parallel-group randomized study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14408DOI Listing
February 2019

Risk of diagnostic delay in congenital thrombotic thrombocytopenic purpura.

J Thromb Haemost 2019 Feb 14. Epub 2019 Feb 14.

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy.

Thrombotic thrombocytopenic purpura (TTP) is an acute life-threatening disorder characterized by multiple organ ischemia due to disseminated thrombi formation in the microvasculature. The congenital form of the disease (Upshaw-Schulman syndrome) is related to ADAMTS13 mutations. Adulthood-onset of TTP does not exclude the congenital form of the disease and a diagnostic delay may account for a great morbidity burden in these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14409DOI Listing
February 2019

Human Neutrophil Peptide-1 Inhibits Thrombus Formation Under Arterial Flow via Its Terminal Free Cysteine Thiols.

J Thromb Haemost 2019 Feb 11. Epub 2019 Feb 11.

Division of Laboratory Medicine, Department of Pathology.

Background: Human neutrophil peptides (HNPs), also known as α-defensins, are released from degranulated neutrophils and play an important role in innate immunity. However, their biological roles in hemostasis under flow are not fully explored.

Objective: This study aims to determine the role of HNP-1 on platelet adhesion and aggregation on a collagen surface or ultra large von Willebrand factor (ULVWF) on endothelium under flow and elucidate the structural elements required for its activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14407DOI Listing
February 2019

Factor VIIa-induced interaction with integrin controls the release of tissue factor on extracellular vesicles from endothelial cells.

J Thromb Haemost 2019 Feb 11. Epub 2019 Feb 11.

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, USA.

Background: Cell injury signal-induced activation and release of tissue factor (TF) on extracellular vesicles (EV) from immune and vessel wall cells propagate local and systemic coagulation initiation. TF trafficking and release on EV occurs in concert with the release of cell adhesion receptors, including integrin β1 heterodimers which control trafficking of the TF-FVIIa complex. Activation of the TF signaling partner, protease activated receptor (PAR) 2, also triggers TF release on integrin β1 EV from endothelial cells, but the physiological signals for PAR2-dependent EV generation at the vascular interface remain unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14406DOI Listing
February 2019

New functional test for the TFPIα cofactor activity of Protein S working in synergy with FV-Short.

J Thromb Haemost 2019 Feb 11. Epub 2019 Feb 11.

Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö, Sweden.

Background: Protein S is an anticoagulant cofactor to both activated protein C and tissue factor pathway inhibitor (TFPIα). The TFPIα-cofactor activity of protein S is stimulated by a short isoform of factor V (FV-Short), the two proteins functioning in synergy.

Objective: Using the synergistic TFPIα-cofactor activity between protein S and FV-Short to develop a functional test for plasma protein S. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14405DOI Listing
February 2019
1 Read

The endothelial lectin clearance receptor CLEC4M binds and internalizes Factor VIII in a VWF-dependent and -independent manner.

J Thromb Haemost 2019 Feb 11. Epub 2019 Feb 11.

Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada.

Background: von Willebrand factor (VWF) and factor VIII (FVIII) circulate in the plasma as a non-covalent complex, and the majority of FVIII is likely cleared by VWF-dependent pathways. Clearance of VWF-free FVIII is rapid and underlies the pathological basis of some quantitative FVIII deficiencies. The receptor pathways that regulate the clearance of VWF-bound and VWF-free FVIII are incompletely uncharacterized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14404DOI Listing
February 2019
4 Reads

Corrigendum.

Authors:

J Thromb Haemost 2019 Feb 12;17(2):422. Epub 2018 Aug 12.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14252DOI Listing
February 2019

Establishment of the WHO 2nd International Standard Factor V, plasma (16/374): Communication from the SSC of the ISTH.

J Thromb Haemost 2019 Feb 7. Epub 2019 Feb 7.

National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, UK.

The WHO International Standard (WHO IS) for Factor V in plasma defines the International Unit (IU) for factor V clotting activity and thereby supports the quantification, harmonisation and long-term continuity of measurements internationally. Measurement of factor V in plasma is pertinent to the diagnosis of rare bleeding disorders as well as being a quality control marker for solvent-detergent treated fresh, frozen human plasma [1,2]. Declining stocks of the WHO 1st IS (NIBSC code: 03/116) has made it necessary to prepare a replacement standard and this report describes the value assignment of the WHO 2nd IS Factor V plasma (16/374) for clotting activity and a new analyte, factor V antigen. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14403DOI Listing
February 2019
1 Read

Sodium-site in serine protease domain of human coagulation factor IXa: evidence from the crystal structure and molecular dynamics simulations study.

J Thromb Haemost 2019 Feb 6. Epub 2019 Feb 6.

Department of Orthopaedic Surgery, University of California, Los Angeles, CA, 90095, USA.

Background: Activated coagulation factor IX (FIXa) consists of a γ-carboxyglutamic acid domain, two epidermal growth factor-like (EGF) domains and C-terminal protease domain. Consensus sequence and biochemical data support the existence of Na -site in FIXa protease domain. However, soaking experiments or crystals grown in high concentration of ammonium sulfate did not reveal Na -site in wild-type or mutant FIXa EGF2/protease domain structure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14401DOI Listing
February 2019
1 Read

Recurrent venous thromboembolism patients form clots with lower elastic modulus than those with non-recurrent disease.

J Thromb Haemost 2019 Feb 6. Epub 2019 Feb 6.

Leeds Thrombosis Collective, Department of Discovery and Translational Science, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, UK.

Background: Venous thromboembolism (VTE) is associated with a high risk of recurrent events after withdrawal of anticoagulation.

Objectives: The aim of this study was to determine the difference in plasma clot mechanical properties from patients having recurrent (r) versus non-recurrent (nr) VTE.

Methods: We previously developed a system for determining clot mechanical properties using an in-house magnetic tweezers system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14402DOI Listing
February 2019
2 Reads

Revisiting the role of therapeutic plasma exchange in the management of catastrophic antiphospholipid syndrome.

J Thromb Haemost 2019 Feb 5. Epub 2019 Feb 5.

Thomas Jefferson University Hospital, Philadelphia, PA.

As apheresis providers, we are very interested in actively collaborating with multidisciplinary care teams that refer patients for our procedures. We read with interest the recently published McMaster RARE-Bestpractices clinical practice guideline on the diagnosis and management of catastrophic antiphospholipid syndrome (CAPS) [1]. However, the clinical practice guideline had several shortcomings that call into question the authors' conclusion that therapeutic plasma exchange (TPE) should be used as first-line therapy. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/jth.14400
Publisher Site
http://dx.doi.org/10.1111/jth.14400DOI Listing
February 2019
2 Reads

Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies: reply.

Authors:
Keiji Nogami

J Thromb Haemost 2019 Feb 1. Epub 2019 Feb 1.

Department of Pediatrics, Nara Medical University, Kashihara, Nara, 634-8522, Japan.

Emicizumab is a humanized, recombinant bispecific monoclonal antibody to factor IX/IXa and factor X/Xa that mimics the cofactor function of factor VIIIa by positioning factor IXa and factor X suitably to promote the enzymatic activity of factor IXa in the tenase complex. Emicizumab recognizes the epidermal growth factor (EGF)-like domain 1 of factor IX/IXa with one arm, and the EGF-like domain 2 of factor X/Xa with the other arm. This bispecific antibody does not induce antibody-dependent accumulation of factor IX/IXa and/or factor X/Xa in circulation due to much weaker binding than those of other therapeutic monoclonal antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14393DOI Listing
February 2019
1 Read

A Unique Protein Kinase C-Dependent Pathway for Tissue Factor Downregulation in Pericytes.

J Thromb Haemost 2019 Jan 30. Epub 2019 Jan 30.

Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA.

Background: Embryonic- and tumor-associated angiogenesis are linked to elevated expression of the pro-coagulant transmembrane receptor, tissue factor (TF). By contrast, we have reported that high baseline TF expression by perivascular cells (pericytes) is dramatically reduced during angiogenesis at sites of wound healing. This is the only setting in which active TF downregulation has been reported, thus revealing a novel mechanism of TF regulation. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jth.14399
Publisher Site
http://dx.doi.org/10.1111/jth.14399DOI Listing
January 2019
3 Reads

The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism: comment.

J Thromb Haemost 2019 Jan 28. Epub 2019 Jan 28.

Department of Health Information Management, School of Allied Medical Sciences, Kermanshah University of Medical Sciences, Kermanshah, Iran.

We read with interest the article recently published in Journal of Thrombosis and Haemostasis entitled "The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism". The goal of this study was to evaluate the ability of the American College of Chest Physicians (ACCP) score to predict the risk of bleeding in an inception cohort of patients belonging to an Italian Register (START2), who had long-term anticoagulation. To do this, 2263 patients participated in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14397DOI Listing
January 2019

What the Neighbors Say.

Authors:

J Thromb Haemost 2019 Jan 28. Epub 2019 Jan 28.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14390DOI Listing
January 2019

The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism: reply.

J Thromb Haemost 2019 Jan 28. Epub 2019 Jan 28.

Hematology Department, S. Bortolo Hospital, Vicenza, Italy.

We thank Drs Daraz and Shahsavari for their comments on our manuscript. We fully agree that several steps are required to fully validate a prediction model before proposing it for clinical guidance. Indeed, the aim of our study was not to develop a new prediction model to assess the risk of bleeding during anticoagulation, but rather to perform an external validation on an already proposed prediction model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14396DOI Listing
January 2019

Direct Oral Anticoagulants in Patients with Venous Thromboembolism and Thrombophilia: A Systematic Review and Meta-Analysis.

J Thromb Haemost 2019 Jan 28. Epub 2019 Jan 28.

Winship Cancer Institute of Emory University, Atlanta, GA, USA.

Background: Direct oral anticoagulants (DOACs) are increasingly used in acute and long-term treatment of venous thromboembolism (VTE). However, their role in management of thrombophilia-associated VTE is controversial.

Methods: Through a comprehensive search on MEDLINE, Cochrane Library and Clinicaltrials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14398DOI Listing
January 2019

Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies: comment.

J Thromb Haemost 2019 Jan 23. Epub 2019 Jan 23.

Department of Hematology and Oncology.

Emicizumab [1, 2], which is a bispecific antibody for clotting factor X (FX) and FIX, is useful for threating hemophilic patients with inhibitors for FVIII and it can reduce the injection frequency for FVIII products in the treatment of hemophilia A. However, measuring the FVIII activity and inhibitors for FVIII is difficult to carry out in hemophilic patients treated with emicizumab. Although hemophilic patients with inhibitors should be treated with bypass therapy at the time of major surgery or severe bleeding, the inhibitors for FVIII cannot be evaluated in patients treated with emicizumab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14395DOI Listing
January 2019
2 Reads

Laboratory Assay Measurement of Modified Clotting Factor Concentrates: A Review of the Literature and Recommendations for Practice.

J Thromb Haemost 2019 Jan 22. Epub 2019 Jan 22.

Cambridge Haemophilia& Thrombophilia Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Over the past several years, novel modified clotting factor concentrates (CFC) have been introduced into practice and are now widely prescribed in the countries where they are licensed. These products allow for less frequent infusions of CFC thereby providing improved convenience and/or higher trough levels. They have been extensively studied for prophylaxis, episodic treatment of bleeding and for surgical prophylaxis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14394DOI Listing
January 2019
1 Read

Loss of fibrinogen in zebrafish results in an asymptomatic embryonic hemostatic defect and synthetic lethality with thrombocytopenia.

J Thromb Haemost 2019 Jan 21. Epub 2019 Jan 21.

Department of Pediatrics, University of Michigan, Ann Arbor, MI, 48109-5646, USA.

Background: Mutations in the alpha chain of fibrinogen (FGA), like deficiencies in other fibrinogen subunits, lead to rare inherited autosomal recessive hemostatic disorders. These range from asymptomatic to catastrophic life-threatening bleeds, and the molecular basis of inherited fibrinogen deficiencies is only partially understood. Zinc finger nucleases have been used to produce mutations in zebrafish fga, resulting in overt adult onset hemorrhage and reduced survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14391DOI Listing
January 2019
1 Read

Clinical pharmacology, efficacy and safety study of a triple-secured fibrinogen concentrate in adults and adolescent patients with congenital fibrinogen deficiency.

J Thromb Haemost 2019 Jan 20. Epub 2019 Jan 20.

Hematology division, Hemophilia Comprehensive Care Center Louis Pradel Hospital, University Lyon 1, Bron, France.

Background: Single-factor replacement therapy is considered the most suitable treatment option for hereditary fibrinogen deficiency. A triple-secured plasma-derived human fibrinogen product was developed to increase the safety of the former fibrinogen concentrate.

Objectives: This non-randomized, open-label, prospective study investigated pharmacokinetics, efficacy and safety of a novel fibrinogen concentrate (FibCLOT /CLOTTAFACT LFB, France) in inherited deficiency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14392DOI Listing
January 2019
4 Reads

Virus envelope tissue factor promotes infection in mice.

J Thromb Haemost 2019 Jan 19. Epub 2019 Jan 19.

Center for Innovation, Canadian Blood Services, Vancouver, Canada.

Background: Tissue factor (TF) is the essential cell-surface initiator of coagulation and mediates cell signaling through protease activated receptor (PAR) 2. Having a diverse cellular distribution, TF is involved in many biological pathways and pathologies. Our earlier work identified host-cell derived TF on the envelope covering several viruses and showed its involvement toward enhanced cell infection in vitro. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14389DOI Listing
January 2019
6 Reads

Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in management of major bleeding.

J Thromb Haemost 2019 Jan 18. Epub 2019 Jan 18.

Department of Pharmacy, OLVG, Amsterdam, the Netherlands.

Essentials In 2016 the SSC proposed definitions for effective hemostasis in management of major bleeding. To validate these definitions, we studied the use in three large anticoagulant-reversal studies. Method agreement analysis and interobserver reliability showed at least acceptable agreement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14388DOI Listing
January 2019
1 Read

Effect of anticoagulant treatment on pain in distal deep vein thrombosis: an ancillary analysis from the cactus trial.

J Thromb Haemost 2019 Jan 17. Epub 2019 Jan 17.

Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Thrombosis Research Group, Ottawa, Canada.

Essentials Management of patients with calf deep vein thrombosis remains controversial. We conducted a post-hoc analysis of a placebo controlled LMWH randomized clinical trial. Pain was assessed using visual analogue scale at inclusion, one and six weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14387DOI Listing
January 2019
1 Read

Vascular protease-activated receptor 4 upregulation, increased platelet aggregation, and coronary lipid deposits induced by long-term dabigatran administration - results from a diabetes animal model.

J Thromb Haemost 2019 Jan 17. Epub 2019 Jan 17.

University of Medicine and Pharmacy of Tîrgu Mureș, Tîrgu Mureș, Romania.

Essentials The impact of long-term thrombin inhibition outside the coagulation cascade is far from clear. We aimed to assess the impact of dabigatran etexilate (DE) in diabetic and control rats. In diabetic rats, DE increased platelet aggregation and lead to coronary lipid deposits. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14386DOI Listing
January 2019
2 Reads

Novel therapies for hemophilia A - the role of the von Willebrand factor chaperone.

J Thromb Haemost 2019 Jan 16. Epub 2019 Jan 16.

Haemostasis Research Group, Department of Molecular and Cellular Therapeutics, Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14353DOI Listing
January 2019

Sirtilins - the new old members of the vitamin K-dependent coagulation factor family.

J Thromb Haemost 2019 Jan 15. Epub 2019 Jan 15.

Department of Biosciences, University of Salzburg, Salzburg, Austria.

Essentials Blood coagulation is driven by vitamin K (VK)-dependent proteases. We have identified and characterized 'sirtilin' as an additional VK-dependent protease. Sirtilins emerged early in the evolution of the coagulation system of vertebrates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14384DOI Listing
January 2019
2 Reads

What the Neighbors Say.

Authors:

J Thromb Haemost 2019 Feb 15;17(2):246. Epub 2019 Jan 15.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14376DOI Listing
February 2019

Abstract thoughts of hemostasis.

J Thromb Haemost 2019 Feb 15;17(2):245. Epub 2019 Jan 15.

Medical School, Departments of Biological Chemistry & Internal Medicine, University of Michigan, Ann Arbor, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14375DOI Listing
February 2019

An international External Quality Assessment for laboratory diagnosis of Heparin-Induced Thrombocytopenia.

J Thromb Haemost 2019 Jan 14. Epub 2019 Jan 14.

Institut für Immunologie und Transfusionsmedizin, Universitätsmedizin Greifswald, Greifswald, Germany.

Objective: Heparin-induced thrombocytopenia (HIT) is a potentially life-threatening complication of heparin exposure. Diagnosis is most reliable using a combination of an enzyme-immunoassay (EIA) that detects antibodies against platelet factor 4 (PF4)/heparin complexes ("antigen" assay) and a "functional" assay that detects platelet-activating properties of the pathogenic HIT antibodies. No External Quality Assessment (EQA) is available for a combination of the tests. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14383DOI Listing
January 2019
1 Read

Human low-affinity IgG receptor FcγRIIA polymorphism H131R associates with subclinical atherosclerosis and increased platelet activity in systemic lupus erythematosus.

J Thromb Haemost 2019 Jan 14. Epub 2019 Jan 14.

Department of Medicine, Division of Cardiology, NYU Langone Medical Center, New York, NY, USA.

Essentials Systemic lupus erythematosus (SLE) patients are at increased risk for premature CVD. Platelet activity, vascular dysfunction and carotid artery plaque are associated with FcγRIIA genotype in SLE. FcγRIIA genotype was not associated with platelet activity or carotid plaque in healthy controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14385DOI Listing
January 2019
1 Read

Tyrosyl-tRNA synthetase drives megakaryopoiesis independently of thrombopoietin signaling.

J Thromb Haemost 2019 Jan 11. Epub 2019 Jan 11.

Division of Hematology, Brigham and Women's Hospital and Department of Medicine, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14361DOI Listing
January 2019

miR-15a-5p regulates expression of multiple proteins in the megakaryocyte GPVI signaling pathway.

J Thromb Haemost 2019 Jan 10. Epub 2019 Jan 10.

Molecular Medicine Program, University of Utah, Salt Lake City, UT, 84112, USA.

Background: Megakaryocytes (MKs) invest their progeny platelets with proteins and RNAs. MicroRNAs (miRs), which inhibit mRNA translation into protein, are abundantly expressed in MKs and platelets. Although platelet miRs have been associated with platelet reactivity and disease, there is a paucity of information on the function of miRs in human MKs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14382DOI Listing
January 2019

Prevention of relapse in patients with acquired thrombotic thrombocytopenic purpura undergoing elective surgery: a case series.

J Thromb Haemost 2019 Jan 10. Epub 2019 Jan 10.

Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.

Background: Severe ADAMTS13 deficiency has been recognized as the main risk factor for recurrence of thrombotic thrombocytopenic purpura (TTP). Several conditions including surgery may influence the levels of ultra large Von Willebrand factor and ADAMTS13, acting as a trigger for an acute TTP event.

Objectives: To report our experience for management of six patients affected with acquired TTP who underwent elective surgery after a prophylactic treatment to restore ADAMTS13 activity levels. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jth.14381
Publisher Site
http://dx.doi.org/10.1111/jth.14381DOI Listing
January 2019
9 Reads

Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH.

J Thromb Haemost 2019 Feb 7;17(2):415-419. Epub 2019 Jan 7.

Department of Medicine, University College London Hospitals NHS Foundation Trust, London, UK.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jth.14354
Publisher Site
http://dx.doi.org/10.1111/jth.14354DOI Listing
February 2019
8 Reads

Red blood cells: the forgotten player in hemostasis and thrombosis.

J Thromb Haemost 2019 Feb 7;17(2):271-282. Epub 2019 Jan 7.

Department of Cell and Developmental Biology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

New evidence has stirred up a long-standing but undeservedly forgotten interest in the role of erythrocytes, or red blood cells (RBCs), in blood clotting and its disorders. This review summarizes the most recent research that describes the involvement of RBCs in hemostasis and thrombosis. There are both quantitative and qualitative changes in RBCs that affect bleeding and thrombosis, as well as interactions of RBCs with cellular and molecular components of the hemostatic system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14360DOI Listing
February 2019
1 Read

Erratum.

Authors:

J Thromb Haemost 2019 Jan 1;17(1):242. Epub 2019 Jan 1.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14356DOI Listing
January 2019

What the neighbors say.

Authors:

J Thromb Haemost 2019 Jan;17(1)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14352DOI Listing
January 2019

Administration of rFVIIa to concizumab-dosed monkeys is safe and concizumab does not affect the potency of rFVIIa in hemophilic rabbits.

J Thromb Haemost 2019 Jan 7. Epub 2019 Jan 7.

Global Drug Discovery, Novo Nordisk A/S, Måløv, Denmark.

Background: Concizumab, a monoclonal antibody against tissue factor pathway inhibitor (TFPI), is currently in clinical development as a subcutaneous prophylactic therapy for hemophilia A/B with and without inhibitors. In patients with inhibitors, treatment choice for break-through bleeding will be bypassing agents, e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14380DOI Listing
January 2019
2 Reads

J. Evan Sadler III MD PhD (9 November 1951 - 13 December 2018).

Authors:

J Thromb Haemost 2019 Feb 7;17(2):420-421. Epub 2019 Jan 7.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14373DOI Listing
February 2019

Diagnosis of hereditary platelet disorders in the era of next-generation sequencing: "primum non nocere".

J Thromb Haemost 2019 Jan 5. Epub 2019 Jan 5.

Institut für Immunologie und Transfusionsmedizin, Universitätsmedizin Greifswald, Greifswald, Germany.

Inherited platelet disorders can affect "only platelets", occur as a "syndromic phenotype" or be associated with "increased risk of hematological malignancies". Genetic testing is attractive for diagnosis of inherited platelet disorders. However, many physicians who refer patient blood for genetic testing are unaware of the association of certain inherited platelet disorders with other risks. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jth.14377
Publisher Site
http://dx.doi.org/10.1111/jth.14377DOI Listing
January 2019
5 Reads

Towards patient-specific management of trauma hemorrhage: the effect of resuscitation therapy on parameters of thromboelastometry.

J Thromb Haemost 2019 Jan 4. Epub 2019 Jan 4.

Department of Intensive Care Medicine, Academic Medical Center, The Netherlands.

Background: Rotational Thromboelastometry (ROTEM ) can detect trauma-induced coagulopathy (TIC) and is used in transfusion algorithms. The response of ROTEM to transfusion therapy is unknown.

Objectives: To determine the response of ROTEM profiles to therapy in bleeding trauma patients. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jth.14378
Publisher Site
http://dx.doi.org/10.1111/jth.14378DOI Listing
January 2019
9 Reads

The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.

J Thromb Haemost 2019 Jan 4. Epub 2019 Jan 4.

Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI, USA.

Essentials Platelet-specific FVIII gene therapy is effective in hemophilia A mice even with inhibitors. The impact of platelet adherence via VWF/GPIbα binding on platelet gene therapy was investigated. GPIbα does not significantly affect platelet gene therapy of hemophilia A with inhibitors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14379DOI Listing
January 2019

von Willebrand factor/ADAMTS-13 interactions at birth: implications for thrombosis in the neonatal period.

J Thromb Haemost 2018 Dec 29. Epub 2018 Dec 29.

Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, USA.

von Willebrand factor (VWF) and its cleaving protease ADAMTS-13 (A Disintegrin and Metalloproteinase with Thrombospondin type 1 motif, member 13) are essential components to hemostasis. These plasma proteins have also been implicated in a number of disease states, including those affecting children. The best described abnormality is the congenital form of thrombotic thrombocytopenic purpura (TTP) resulting from germline mutations in the ADAMTS-13 gene. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jth.14374
Publisher Site
http://dx.doi.org/10.1111/jth.14374DOI Listing
December 2018
8 Reads

Imminent risk of a global shortage of heparin caused by the African Swine Fever afflicting the Chinese pig herd.

J Thromb Haemost 2019 Feb 1;17(2):254-256. Epub 2019 Feb 1.

Laboratório de Tecido Conjuntivo, Hospital Universitário Clementino Fraga Filho and Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

Most of the unfractionated and low-molecular-weight heparins available worldwide are produced by Chinese companies from porcine mucosa. China is the world's largest producer of pork and thus has plenty of raw material to produce heparins. However, the deadly African Swine Fever (ASF) outbreaks afflicting China since August 2018 may cause extensive losses to the pig herd, with serious consequences for the global supply of heparins. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14372DOI Listing
February 2019

Derangement of the endothelial glycocalyx in sepsis.

Authors:
T Iba J H Levy

J Thromb Haemost 2019 Feb 3;17(2):283-294. Epub 2019 Feb 3.

Department of Anesthesiology, Critical Care, and Surgery, Duke University School of Medicine, Durham, NC, USA.

The vascular endothelial surface is coated by the glycocalyx, a ubiquitous gel-like layer composed of a membrane-binding domain that contains proteoglycans, glycosaminoglycan side-chains, and plasma proteins such as albumin and antithrombin. The endothelial glycocalyx plays a critical role in maintaining vascular homeostasis. However, this component is highly vulnerable to damage and is also difficult to examine. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jth.14371
Publisher Site
http://dx.doi.org/10.1111/jth.14371DOI Listing
February 2019
2 Reads

Blood clot contraction differentially modulates internal and external fibrinolysis.

J Thromb Haemost 2019 Feb 6;17(2):361-370. Epub 2019 Feb 6.

Department of Cell and Developmental Biology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

Essentials Clot contraction influences the rate of fibrinolysis in vitro. Internal fibrinolysis is enhanced ∼2-fold in contracted vs. uncontracted blood clots. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14370DOI Listing
February 2019

Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia.

J Thromb Haemost 2019 Feb;17(2):389-399

Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.

Essentials Many patients produce antibodies but few lead to heparin-induced thrombocytopenia (HIT). Pathogenic epitopes are difficult to identify as HIT antibodies are polyclonal and polyspecific. KKO binding to platelet factor 4 (PF4) depends on 13 amino acids, three of which are newly observed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14369DOI Listing
February 2019
2 Reads

Unexpected role of natural killer cell-derived interferon-γ as a driver of NETosis and DVT.

J Thromb Haemost 2019 Feb;17(2):400-402

Center for Thrombosis and Hemostasis (CTH), University Medical Center Mainz, Mainz, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14368DOI Listing
February 2019

Individual risk factors predictive of venous thromboembolism in patients with temporary lower limb immobilization due to injury: a systematic review.

J Thromb Haemost 2019 Feb 7;17(2):329-344. Epub 2019 Feb 7.

Thrombosis and Haemophilia Centre, St Thomas' Hospital, London, UK.

Essentials Thromboprophylaxis after lower limb injury is often based on complex risk stratification. Our systematic review identified variables predicting venous thromboembolism (VTE) in this group. Age and injury type were commonly reported to increase the odds of VTE (odds ratio 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14367DOI Listing
February 2019